PMID- 19149741
OWN - NLM
STAT- MEDLINE
DCOM- 20090302
LR  - 20191111
IS  - 1872-213X (Print)
IS  - 1872-213X (Linking)
VI  - 3
IP  - 1
DP  - 2009 Jan
TI  - Targeting hypoxia-inducible factor-1 (HIF-1) signaling in therapeutics: 
      implications for the treatment of inflammatory bowel disease.
PG  - 1-16
AB  - In response to hypoxia, adaptive hypoxia-inducible factor-1 (HIF-1) signaling 
      events are activated to increase oxygen transport, anaerobic energy production 
      and protective pathways to minimize ischemic tissue damage. Although the 
      activation and subsequent induction of gene transcription by HIF-1 is normally 
      associated with hypoxia, it is now established that HIF-1 signaling can be 
      triggered under inflammatory conditions. HIF-1 has been implicated in a number of 
      inflammatory diseases including rheumatoid arthritis, allergic asthma, psoriasis 
      and inflammatory bowel disease (IBD). In the gastrointestinal tract, 
      HIF-1-regulated gene products, such as vascular endothelial growth factor, 
      intestinal trefoil factor and CD73, have been shown to provide protection in 
      animal models of intestinal inflammation. Given the importance of HIF-1 signaling 
      in the aforementioned diseases, there exists considerable interest in the 
      development of methods to modulate HIF-1 expression as well as down-stream 
      signaling events. This review examines HIF-1 signaling with a special focus on 
      the gastrointestinal tract. The patents pertaining to the modulation of HIF-1 
      signaling are summarized, and their relevance to the treatment of inflammatory 
      bowel disease is discussed.
FAU - Hirota, Simon A
AU  - Hirota SA
AD  - Smooth Muscle Research Group, Department of Biochemistry and Molecular Biology, 
      University of Calgary, Alberta, Canada.
FAU - Beck, Paul L
AU  - Beck PL
FAU - MacDonald, Justin A
AU  - MacDonald JA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Recent Pat Inflamm Allergy Drug Discov
JT  - Recent patents on inflammation & allergy drug discovery
JID - 101309297
RN  - 0 (Hypoxia-Inducible Factor 1)
SB  - IM
MH  - Animals
MH  - *Drug Delivery Systems
MH  - Gastrointestinal Tract/metabolism/physiopathology
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Hypoxia-Inducible Factor 1/*drug effects/metabolism
MH  - Inflammatory Bowel Diseases/*drug therapy/physiopathology
MH  - Patents as Topic
MH  - Signal Transduction/drug effects
RF  - 169
EDAT- 2009/01/20 09:00
MHDA- 2009/03/03 09:00
CRDT- 2009/01/20 09:00
PHST- 2009/01/20 09:00 [entrez]
PHST- 2009/01/20 09:00 [pubmed]
PHST- 2009/03/03 09:00 [medline]
AID - 10.2174/187221309787158434 [doi]
PST - ppublish
SO  - Recent Pat Inflamm Allergy Drug Discov. 2009 Jan;3(1):1-16. doi: 
      10.2174/187221309787158434.